Research Papers:
PPARGC1A rs3736265 G>A polymorphism is associated with decreased risk of type 2 diabetes mellitus and fasting plasma glucose level
Metrics: PDF 2074 views | HTML 2487 views | ?
Abstract
Li Zhu1,*, Qiuyu Huang2,*, Zhiqiang Xie3,*, Mingqiang Kang4, Hao Ding5, Boyang Chen4, Yu Chen6, Chao Liu7, Yafeng Wang8 and Weifeng Tang4
1Department of Nephrology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China
2Department of Cardiac Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
3Department of Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
4Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
5Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China
6Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China
7Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China
8Department of Cardiology, The People's Hospital of Xishuangbanna Dai Autonomous Prefecture, Jinghong, Yunnan Province, China
*These authors have contributed equally to this work
Correspondence to:
Weifeng Tang, email: [email protected]
Yafeng Wang, email: [email protected]
Keywords: PPARG, PPARGC1A, PPARGC1B, polymorphism, type 2 diabetes mellitus
Received: January 05, 2017 Accepted: February 13, 2017 Published: March 17, 2017
ABSTRACT
It has been reported that peroxisome proliferator-activated receptor gamma (PPARG) and peroxisome proliferator-activated receptor gamma co-activator 1 (PPARGC1) family (e.g. PPARGC1A and PPARGC1B) are key agents in the development and pathophysiology of type 2 diabetes mellitus (T2DM). In this study, we designed a case-control study and selected PPARG rs1801282 C>G, PPARG rs3856806 C>T, PPARGC1A rs8192678 C>T, PPARGC1A rs2970847 C>T, PPARGC1A rs3736265 G>A, PPARGC1B rs7732671 G>C and PPARGC1B rs17572019 G>A polymorphisms to assess the relationship between these polymorphisms and T2DM using the SNPscan method. A total of 502 T2DM patients and 784 non-diabetic controls were enrolled. We found that PPARGC1A rs3736265 G>A polymorphism was correlated with a borderline decreased susceptibility of T2DM. In a subgroup analysis by age, sex, alcohol use, smoking status and body mass index, a significantly decreased risk of T2DM in <65 years and female groups was found. Haplotype comparison analysis indicated that CTTCGGG and CTCTGGG haplotypes with the order of PPARG rs1801282 C>G, PPARG rs3856806 C>T, PPARGC1A rs8192678 C>T, PPARGC1A rs2970847 C>T, PPARGC1A rs3736265 G>A, PPARGC1B rs7732671 G>C and PPARGC1B rs17572019 G>A polymorphisms in gene position significantly increased the risk of T2DM. However, CCCCACA haplotype conferred a decreased risk to T2DM. We also found that PPARGC1A rs3736265 A allele decreased the level of fasting plasma glucose (FPG), while increased the level of Triglyceride. In conclusion, Our findings suggest that variants of PPARGC1A rs3736265 G>A polymorphism decrease the level of FPG, improving the expectation of study in individual's prevention strategies to T2DM.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16307